Description of the development process
On May 25th, 20021year, China Biopharmaceutical replied that Kexing Zhongwei's parent company Kexing Holding Biotechnology Co., Ltd. is a listed company in the US stock market, and its performance will be announced next week.
On July 25th, the Vaccine Evaluation Institute of Jiangsu Provincial Center for Disease Control and Prevention, together with Fudan University School of Public Health, Kexing Holding Biotechnology Co., Ltd. Kexing, Huashan Hospital affiliated to Fudan University and other units, uploaded the second issue entitled "Immunogenicity and Safety of Clover III to Healthy Adults Aged 18-59, and Immune Persistence of Double-blind, Randomized and Placebo Control" on the platform of health science preprint.